Skip to main content
. 2021 Oct 1;37(4):372–373. doi: 10.4103/iju.iju_292_21

Table 1.

Various trials on 177Lu-PSMA617 in metastatic castration resistance prostate cancer

Study VISION trial[1] TheraP trial[2] Yadav et al.[3]
Interventional drug 177Lu-PSMA617 177Lu-PSMA617 177Lu-PSMA617
Control Standard therapy alone Cabazitaxel -
Study population Progressive mCPRC who already received ADT along with taxane regimen mCRPC patients who already received ADT Progressive mCRPC patients on ADT and/or taxane chemotherapy
Study design Phase 3, RCT Phase 2 unblinded RCT Single-arm prospective study
Sample size 831 200 90
Allotment 2:1 1:1 -
Primary outcome OS
IB-PFS
PSA response OS
IB-PFS 8.7 months versus 3.4 months
OS 15.3 months versus 11.3 months Yet to report 14 months
PSA response rate 46% versus 7.1% (>50% response)
33% versus 2% (>80% response)
66% versus 37% 45% at the end of assessment
Adverse events (Grade 3-4) 52.7% versus 38% 33% versus 45% No adverse events

IB-PFS=Imaging-based progression-free survival, OS=Overall survival, RCT=Randomized control trial, ADT=Androgen deprivation therapy, mCRPC=Metastatic castration resistance prostate cancer, PSA=Prostate-specific antigen